The RSA grant has been awarded towards the project of scaling up manufacturing facilities for the Company's new CD4 test for monitoring HIV positive patients. The facility will be located at the Company's Headquarters in Alva, Central Scotland and the grant will be payable in three instalments dependent on the attainment of employment targets and capital expenditure.  The project is split into two phases; the first phase being conversion of a part of the existing premises to meet initial customer demand and a second phase to allow further scale up to meet future anticipated demand.  It is expected that a first instalment of £32,000 will be received in the current financial year.